Close Menu

Breaking News

The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019. 

The Church Lab spinout has now raised more than $50 million to develop and commercialize its fluorescent in situ sequencing technology for spatial genomics.

Quidel said that it expects fourth quarter 2019 revenues to be in the range of $151 million to $152 million, which would eclipse analyst expectations.

The firm also announced an exclusive distribution deal covering Israel for its T2 Resistance, T2Bacteria, and T2Candida panels

The company said it delivered 4,480 DecisionDx-Melanoma test reports in Q4 2019 compared to 3,270 reports in Q4 2018.

The San Diego-based company plans to develop a flexible, modular, and high-performing sequencing platform based on proprietary technologies in different areas.

A genome-wide association meta-analysis involving almost one million heart failure cases and controls identified 11 risk loci and helped distinguish potential causal contributors.

The clinical study will evaluate a next-generation sequencing-based test, which has the potential to detect all known respiratory pathogens in 12 hours.

The San Diego firm has now raised at least $145 million to drive development of its DNA sequencing platform and build manufacturing and commercial operations.

The deal follows a number of recent acquisitions in the animal genomics space for Neogen including Canadian animal genomics firm Delta Genomics Centre.

The additional funds follow the $25 million that the company announced in May 2019, bringing the total figure for the round to $45 million.

The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.

The investigators used gene expression, chromatin interaction, and functional annotations to prioritize 191 genes as targets of potentially causal variants.

The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.

Researchers discovered a duplication affecting the RYR2 gene in two families, which may indicate that it is a founder mutation in the Amish population.

Some of these shared loci were associated with higher BMI, but some were linked to lower BMI, particularly those also linked to schizophrenia.

The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.

In a large group of participants followed for decades, baseline body mass index outperformed a SNP-based obesity risk score for predicting midlife weight.

The firm said its panel, which runs on its MDx-3000 system, tests nasopharyngeal swabs for the most common viruses and bacteria.

The new guidelines are meant to assist medical professionals in understanding the complexity and implications of exome sequencing in prenatal care.

The partners will focus on optimizing technology and conducting clinical utility studies for liquid biopsy and tissue-based genomic applications.

Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.

Veracyte will provide Acerta Pharma, a division of AstraZeneca, with genomic information to support its development of oncology therapeutics.

Palmetto has expanded coverage of the ClonoSeq assay to include monitoring MRD testing for patients with chronic lymphocytic leukemia (CLL.)

The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities. 

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.